Bayesian Causal Atlas · Vol. Endocrinology · Pearl Structural Causal Model
Type 2 Diabetes Mellitus — Structural Causal Analysis
In plain wordsType-2 diabetes affects about 38 million US adults and drives heart, kidney, and other disease. This tool shows how much treatments lower serious heart events. Important: just lowering blood sugar is not enough — one trial found pushing it too hard raised deaths. Best-case research estimates, not medical advice.
Type 2 diabetes affects roughly 38 million United States adults and is a master driver of cardiovascular disease, chronic kidney disease, retinopathy and premature death. This oracle estimates the causal reduction in major adverse cardiovascular events and mortality on a shared glycaemia → weight → cardiorenal-risk backbone, using hazard ratios from named cardiovascular-outcome trials. It separates agents with direct cardiorenal benefit (SGLT2 inhibitors, GLP-1 agonists, finerenone) from glucose-lowering that is cardiovascular-neutral (sulfonylureas, insulin). For education, not individual medical advice.
Method. Structural Causal Model (SCM) in Judea Pearl's framework. What this engine does and does not do: it does not itself perform backdoor adjustment — every hazard ratio is taken from a named trial or a confounder-adjusted study, so the backdoor adjustment is the source study's, and the named confounders below are the paths those studies adjusted for. What this engine adds is the combination rule. Interventions are not assumed independent: shared-mechanism arms overlap on hyperglycaemia, adiposity and cardiorenal risk, and that overlap is removed by an eigenvalue-corrected model at an adjustable mean cross-correlation ρ̄ (default 0.30). Robustness to unmeasured confounding is quantified with the E-value. PN / PS / PNS under monotonicity. Every hazard ratio is cited; surrogate, subgroup and failed-confirmatory figures are flagged. The front door is resolved through an EXPLICIT mediator cascade (glycaemic → weight / → cardiorenal → disease state), not one lumped node: each intervention acts on a specific node, so same-node interventions are substitutes that saturate against each other, while different-node interventions are d-separated given the intermediate node and compose in series. The cross-correlation removal thus follows from the graph structure; the residual ρ̄ cleans up only the mediator-independent (direct) effects.
ρ̄ = 0.30
A–D (all)
A high (RCT/meta) · B cohort · C case-series/modelled · D consensus/provisional. Lower-grade interventions are excluded from the DAG, front-door pooling, Pareto, Monte‑Carlo & sensitivity.
Interventions
Tick the interventions to combine. Each shows its trial effect estimate, 95% confidence interval (CI), E-value, mechanism, and citation. ★ = in the current Pareto effective set but not yet ticked.
Combined causal estimate
Headline is the front-door estimate: shared cardiometabolic overlap removed via dose-response saturation; residual direct-effect overlap removed via the eigenvalue model at ρ̄.
1.00
Combined HR
0%
Relative risk ↓
—
Pooled E-value
Interventions selected (k)
0
Effective independent dimensions (n_eff)
0
Redundancy discount applied
0%
Baseline risk (illustrative anchor)
—
Absolute risk after intervention
—
Absolute risk difference (RD)
—
Backdoor-only HR (no front-door)
—
Mediator overlap removed
—
Number needed to treat (NNT)
—
ρ-sensitivity band (ρ 0 → 0.6)
—
Interpretation
—
Causal attribution
Under monotonicity + exogeneity (E-value bounds the exogeneity assumption).
Probability of Necessity (PN)
—
Probability of Sufficiency (PS)
—
Prob. of Necessity & Sufficiency (PNS, lower bound)
—
Causal DAG
Cross-correlation
Pareto (threshold)
Monte Carlo
Front-door mediation
What-if / If-not-for
Sensitivity
Antithesis
Faithful causal directed acyclic graph (DAG). Each therapy is a node acting through hyperglycaemia, adiposity and cardiorenal risk toward the endpoint (Y); direct-mechanism arms are drawn gold. Named confounders open back-door paths (adjusted). Mediator cascade: interventions attach to the node they act on (glycaemic → weight / → cardiorenal), which converge on the disease state and thence the endpoint — drawing the intermediate mediators explicitly is what exposes d-separation and per-channel saturation.
Eigenvalue diagnostics for the selected interventions under an equicorrelation matrix (off-diagonal ρ̄). A large λmax relative to k signals redundancy; n_eff is the effective number of independent interventions actually contributing.
k (selected)
0
λmax
—
λmin
—
n_eff = (Σλ)² / Σλ²
—
Condition number
—
ρ̄ ≈ 0.30 is defensible on mechanistic grounds: same-mechanism arms converge on hyperglycaemia, adiposity and cardiorenal risk, so stacking them yields diminishing returns, while arms on distinct mechanisms share little and compose. ρ̄ is user-adjustable. Most of the overlap is now handled structurally by the mediator nodes (same-node substitutes saturate); ρ̄ governs only the residual correlation among direct effects.
Minimum-effective-set analysis. Set a target combined risk reduction; the model finds the smallest set of interventions — accounting for front-door mediator overlap — that reaches it, and highlights them. If the target exceeds what all interventions together can achieve, the full set is shown (never an empty one). "Apply" ticks exactly that set.
Target combined risk ↓ ≥ 50%
Monte Carlo propagation. Each selected intervention's log-effect is sampled from a normal distribution implied by its 95% CI; samples are combined with the same eigenvalue overlap discount. 5,000 draws.
Median combined HR
—
95% simulation interval
—
Standard deviation of combined HR
—
P(combined HR < 0.90)
—
Antithesis — challenging this oracle's own conclusions
Glucose lowering is not the same as outcome improvement. ACCORD found that pushing HbA1c below ~6% INCREASED mortality; UKPDS legacy benefit was real but modest. The macrovascular gains here come disproportionately from agents with direct cardiorenal mechanisms (SGLT2 inhibitors, GLP-1 agonists, finerenone), not from the degree of glucose lowering — which is why sulfonylureas and insulin sit near the null.
Cardiovascular-outcome-trial effect sizes do not transfer to low-risk patients. LEADER, EMPA-REG and FIDELIO enrolled patients with established disease or CKD; the relative risk reductions shrink in absolute terms in low-risk primary prevention. Applying the trial HRs to a newly diagnosed low-risk patient overstates benefit.
Bariatric surgery and lifestyle are selection machines. Metabolic-surgery mortality data are observational and confounded by who is offered and tolerates surgery; Look AHEAD showed intensive lifestyle did not cut cardiovascular events despite weight loss and remission. Both belong at grade B and their survival HRs are upper bounds.
The class effect is not uniform within a class. GLP-1 and SGLT2i cardiovascular benefits are agent- and endpoint-specific; tirzepatide has no completed CV-outcome trial and its HR here is a projection. Do not read a projected or class-borrowed figure as an agent-specific RCT result.
Adherence, cost and access dominate real-world effectiveness. The newer agents carry substantial cost and GI or genitourinary side-effects; real-world persistence is far below trial adherence, so population effectiveness falls well short of the relative risks shown.
What-if — the do-operator: P(Y | do(S))
Intervening on the selected set S with Pearl's do-operator (setting the interventions, not merely observing them). Contrast against do(∅) = no intervention.
For each intervention: "if not for this one, the combined front-door effect would be…". Isolates each intervention's marginal causal contribution after mediator-overlap removal, so shared-pathway agents are not double-credited.
If not for…
HR without it
HR with full set
marginal RRR lost
One-at-a-time sensitivity. Each intervention's effect is swung across its 95% confidence interval (others held at point estimate); the bar is the resulting swing in the combined front-door effect. A long bar means the combined estimate leans heavily on that single trial's precision.
Optimistic bound (all at CI-low)
—
Point estimate
—
Pessimistic bound (all at CI-high)
—
Pooled E-value (confounding robustness)
—
Front-door-structured mediation decomposition (not front-door identification). Each log-effect splits into a mediated (indirect) and a mediator-independent (direct) part. Indirect parts are routed through the mediator cascade: arms on the SAME node are substitutes and saturate against a dose-response ceiling; arms on DIFFERENT nodes are d-separated and compose in series. No correlation coefficient is applied to the mediated path. ρ̄ is applied ONLY to the un-mediated direct residual. Caveat: Pearl's front-door criterion would additionally require the mediator to be COMPLETE (no unblocked X→Y path bypassing M) and the M→Y edge to be unconfounded — neither is defended arm-by-arm here, and baseline severity routinely confounds M→Y. These are therefore structured decompositions, not identified causal effects. Here mediated effects are pooled WITHIN each cascade node (dose-response saturation of substitutes) and composed in SERIES across nodes (d-separated channels), with the per-node reductions reported so the channel structure is visible.
Mediator saturation cap = 55% cardiometabolic risk ↓
Sum of standalone cardiometabolic reduction (naive)
—
Combined cardiometabolic reduction after saturation
—
Mediator overlap removed (1 - saturation)
—
Direct-effect redundancy removed (1 - n_eff/k)
—
Front-door combined HR
—
Backdoor-only combined HR (comparison)
—
Intervention
HR
%risk↓
med-frac
indirect log
direct log
Which % of cross-correlation is appropriate? Not one number. The mediator overlap is fixed empirically by the cardiometabolic saturation (currently removing — of the summed mediated effect when interventions are stacked). Read every provisional (surrogate / subgroup / observational / failed-confirmatory) entry through its grade, not as an RCT survival result.
Front-door caveat (antithesis): the mediator→outcome edge is confounded by baseline severity and stage; effect sizes are stage-conditional; combined figures are upper bounds that assume the arms stack cleanly.
Executive summary
Select interventions to generate a plain-language summary.